Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.9 (
glucose-6-phosphatase
)
3,081
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We present a case of a 73 year old man, who lost 12 kg of weight in one month, had abdominal pain and progressive hepatic failure. A
MRI
and liver ultrasound were performed and, with the patient's symptoms, hepatocellular carcinoma Vs metastatic liver was suspected. A PET-FDG was performed and the images showed hepatomegaly and splenomegaly, without other findings of interest. FDG distribution in the liver was homogeneous. The patient was diagnosed of hepatocellular carcinoma after liver biopsy. FDG-PET detects only 50 % to 70 % of hepatocellular carcinomas due to varying degrees of activity of the enzyme
glucose-6-phosphatase
in these tumors. This paper reviews the literature on this type of situations.
...
PMID:[FDG-PET in hepatocellular carcinoma. Based on one case]. 1545 Jan 42
Type 1 diabetes is preceded by a long, protracted period of pancreatic islet inflammation by autoreactive lymphocytes. Noninvasive imaging of islet inflammation prior to the onset of hyperglycemia might have diagnostic and therapeutic implications, but this is not currently possible. Here,
MRI
is used to track, noninvasively, the accumulation diabetogenic CD8+ T-cells during type 1 diabetes progression in nonobese diabetic (NOD) mice. The contrast agent is an
MRI
probe (MN-NRP-V7) that specifically labels CD8+ T-cells recognizing residues 206-214 of islet-specific
glucose-6-phosphatase
catalytic subunit related protein (IGRP(206-214)) in the context of the major histocompatibility complex (MHC) class I molecule H-2K(d). This probe consists of superparamagnetic iron oxide nanoparticles (MN) coated with K(d) molecules presenting NRP-V7, a high-avidity mimotope of IGRP(206-214). NOD mice of different ages (5, 8, 15, and 24 weeks) were imaged by
MRI
before and after a single intravenous injection of MN-NRP-V7 or unmodified MN nanoparticles. MN-NRP-V7 accumulation, as determined by semiquantitative
MRI
analysis of pancreas-associated T(2) relaxation time, was antigen-specific, age-dependent, and well correlated with the numbers of MN-NRP-V7-labeled CD8+ T-cells recovered from the pancreata of the treated mice. Antigen/MHC-coupled nanoparticles represent a promising new avenue for noninvasive imaging of lymphocyte inflammation in organ-specific autoimmunity and transplantation.
...
PMID:In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression. 1830 24
PET with
18
F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by
MRI
or PET with other metabolic tracers, including
11
C-methionine, may be missed-for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity.
Methods:
A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both
18
F-FDG and
11
C-methionine PET/CT was retrospectively analyzed.
Results:
In 9 of the 15 patients,
18
F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both
18
F-FDG and
11
C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry,
18
F-FDG-negative myeloma did not exhibit significant differences in HK2 or
glucose-6-phosphatase
expression from
18
F-FDG-positive disease (
P
= 0.57 and
P
= 0.44, respectively).
Conclusion:
Beyond HK2 expression,
18
F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
...
PMID:Hexokinase-2 Expression in
11
C-Methionine-Positive,
18
F-FDG-Negative Multiple Myeloma. 3038 21
